Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosis

Show simple item record Moodie, M en Lal, A en Vidmar, S en Armstrong, DS en Byrnes, Catherine en Carlin, JB en Cheney, J en Cooper, PJ en Grimwood, K en Robertson, CF en Tiddens, HA en Wainwright, CE en 2017-07-27T00:29:57Z en 2014-09 en
dc.identifier.citation Journal of Pediatrics 165(3):564-569.e5 Sep 2014 en
dc.identifier.issn 0022-3476 en
dc.identifier.uri en
dc.description.abstract OBJECTIVES: To determine whether bronchoalveolar lavage (BAL)-directed therapy for infants and young children with cystic fibrosis (CF), rather than standard therapy, was justified on the grounds of a decrease in average costs and whether the use of BAL reduced treatment costs associated with hospital admissions. STUDY DESIGN: Costs were assessed in a randomized controlled trial conducted in Australia and New Zealand on infants diagnosed with CF after newborn screening and assigned to receive either BAL-directed or standard therapy until they reached 5 years of age. A health care funder perspective was adopted. Resource use measurement was based on standardized data collection forms administered for patients across all sites. Unit costs were obtained primarily from government schedules. RESULTS: Mean costs per child during the study period were Australian dollars (AUD)92 860 in BAL-directed therapy group and AUD90 958 in standard therapy group (mean difference AUD1902, 95% CI AUD-27 782 to 31 586, P = .90). Mean hospital costs per child during the study period were AUD57 302 in the BAL-directed therapy group and AUD66 590 in the standard therapy group (mean difference AUD-9288; 95% CI AUD-35 252 to 16 676, P = .48). CONCLUSIONS: BAL-directed therapy did not result in either lower mean hospital admission costs or mean costs overall compared with managing patients with CF by a standard protocol based upon clinical features and oropharyngeal culture results alone. Following on our previous findings that BAL-directed treatment offers no clinical advantage over standard therapy at age 5 years, flexible bronchoscopy with BAL cannot be recommended for the routine management of preschool children with CF on the basis of overall cost savings. en
dc.format.medium Print-Electronic en
dc.language eng en
dc.publisher Elsevier Inc. en
dc.relation.ispartofseries Journal of Pediatrics en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri en
dc.subject Australasian Cystic Fibrosis Bronchoalveolar Lavage Study Investigators en
dc.subject Humans en
dc.subject Cystic Fibrosis en
dc.subject Patient Admission en
dc.subject Bronchoalveolar Lavage en
dc.subject Child, Preschool en
dc.subject Infant en
dc.subject Costs and Cost Analysis en
dc.title Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosis en
dc.type Journal Article en
dc.identifier.doi 10.1016/j.jpeds.2014.05.031 en
pubs.issue 3 en
pubs.begin-page 564 en
pubs.volume 165 en
dc.rights.holder Copyright: Elsevier Inc. en
dc.identifier.pmid 24996984 en
pubs.end-page 569.e5 en
dc.rights.accessrights en
pubs.subtype Article en
pubs.elements-id 445268 en Medical and Health Sciences en School of Medicine en Paediatrics Child & Youth Hlth en
dc.identifier.eissn 1097-6833 en
pubs.record-created-at-source-date 2017-07-27 en
pubs.dimensions-id 24996984 en

Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace